|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||60.71 - 61.34|
|52-week range||40.50 - 68.07|
|PE ratio (TTM)||78.17|
|Earnings date||5 Dec 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||66.18|
The volume and diversity of data sources used in clinical trials are expected to increase significantly over the next three years, according to new research from Tufts Center for the Study of Drug Development.
Veeva Systems is working on a base and near a possible buy zone ahead of its earnings report expected around Nov. 20 .
Veeva Systems today announced it will partner with leading interactive response technology vendors to provide advanced randomization and trial supply management capabilities with Veeva Vault EDC.
Veeva Systems (NYSE: VEEV) today announced Veeva Oncology Link, an enterprise data solution to centralize insights and intelligence on scientific leaders in oncology. Veeva Oncology Link consolidates thousands of global experts and millions of activities, including publications, clinical trials, and events, in a single, complete source of oncology data. Now medical affairs and commercial organizations can better plan and engage top industry thought leaders and create deeper relationships with the global oncology community.
Veeva Systems treaded above its 50-day moving average for the first time in two months after an analyst recommended the stock.
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.
Align Biopharma™, a life sciences industry technology standards group, today published a final open technology standard for identity management. Members from leading pharmaceutical, technology, and service provider companies reviewed and defined the technical requirements for products to enable a single sign-on service for healthcare professionals .
Veeva Systems Inc. , a leading provider of industry cloud solutions for the global life sciences industry, will host its financial analyst and investor day in San Francisco on Wednesday, October 11, 2017.
Accenture (ACN) Collaborates with Veeva Systems. We remain positive on company's sustained focus on product roll outs, along with major acquisitions.
2017 Veeva Global R&D Summit — Veeva Systems today announced that Veeva Vault Development Cloud is gaining momentum as the technology foundation for drug development in life sciences.
Accenture today announced it is working with Veeva Systems , a leader in cloud-based software for the global life sciences industry, to bring Veeva Vault RIM – a transformative regulatory information management solution – to biopharma companies.
Veeva Systems announced that Veeva Vault Quality is helping an increasing number of life sciences customers to modernize quality and content management in the cloud. The number of Vault Quality customers has increased to 120, including four of the top 20 largest biopharmaceutical companies and 30 Veeva Vault QMS customers.
2017 Veeva Global R&D Summit—Veeva Systems announced that Veeva Vault CTMS is gaining momentum with global biopharmaceutical companies and clinical research organizations.
Today at Advamed’s 2017 MedTech Conference, Veeva Systems (NYSE: VEEV) announced that Veeva Vault is helping a growing number of medical device and diagnostics companies improve quality and efficiency to meet new compliance standards. In less than one year, Veeva has seen nearly 25% growth in medical device and diagnostics customers as organizations prepare to meet rigorous compliance requirements from global health authorities and the international standards organization (ISO). Now, nine of the world’s top 15 medical device companies are implementing Veeva Vault, including leaders such BD (Becton, Dickinson and Company).
One of the largest, most in-depth surveys of clinical data management professionals shows that the time it takes companies to design and release clinical study databases is having a negative impact on conducting and completing trials. According to the 2017 eClinical Landscape Study from Tufts Center for the Study of Drug Development, it takes companies an average of 68 days to build and release a clinical study database. Delays in releasing the study database are associated with an increase of nearly a month downstream for other data management processes such as patient data entry and time to lock the database at the end of the study.
Veeva Systems (NYSE: VEEV) announced today that Cancer Research UK selected Veeva Vault eTMF to modernize its clinical trial processes. The organization currently sponsors and manages approximately 25 early phase oncology trials through its Centre for Drug Development. By improving regulatory compliance and increasing efficiency through active trial master file (TMF) management, Cancer Research UK aims to optimize development of new treatments for patients with cancer.
Jim Cramer broke down his thoughts on how reports that North Korea fired a missile that flew over Japan could impact the defense cohort.
Veeva Systems (NYSE: VEEV) announced today that Santhera Pharmaceuticals selected Veeva CRM and Veeva OpenData as a commercial software and data platform for its first product launch. The rare disease pharmaceutical company is adopting Veeva Commercial Cloud solutions to establish a consistent, global approach to commercialization. Accurate customer data is foundational for commercial excellence, especially with today’s growing number of stakeholders.
There is an industrywide drive toward a unified clinical operating model, according to the Veeva 2017 Unified Clinical Operations Survey, one of the industry’s largest annual surveys of clinical operations professionals. The new research from Veeva Systems (NYSE: VEEV) reveals that nearly all respondents cite the need to unify their clinical applications, including EDC, CTMS, and eTMF. Many of the challenges sponsors face today in managing clinical trials stem from the disparate nature of their processes and systems. Respondents use an average of four applications to manage their clinical studies and more than one-third use at least five applications.